Wyeth Materna Case Closes As Firm Runs Out Of Options
This article was originally published in The Tan Sheet
Executive Summary
The U.S. Supreme Court will not hear Wyeth's appeal of a $58.3 mil. judgment for patent fraud and unjust enrichment, ending an 11-year court battle in the Materna prenatal vitamin line case
You may also be interested in...
Wyeth Says Previous Materna Patent Decisions Unfairly Favored State Law
A Colorado federal court decision in an 11 year-old vitamin patent infringement case unfairly allowed state law to override federal laws, according to a petition for writ of certiorari recently filed by Wyeth with the Supreme Court
Wyeth “Unfairly” Delaying Materna Patent Award With Appeal, Innovator Says
Wyeth appealed a $58 mil. patent infringement award for an old prenatal vitamin line to the Supreme Court on Feb. 10, the company said
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC